Type 2 Diabetic Mellitus Related Osteoporosis: Focusing on Ferroptosis

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 May 1

PMID 38693581

Authors

Yili Chen

Wen Zhao

An Hu

Shi Lin

Ping Chen

Bing Yang

Zhirong Fan

Ji Qi

Wenhui Zhang

Huanhuan Gao

Xiubing Yu

Haiyun Chen

Luyuan Chen

Haizhou Wang

Affiliations

Soon will be listed here.

Abstract

With the aging global population, type 2 diabetes mellitus (T2DM) and osteoporosis(OP) are becoming increasingly prevalent. Diabetic osteoporosis (DOP) is a metabolic bone disorder characterized by abnormal bone tissue structure and reduced bone strength in patients with diabetes. Studies have revealed a close association among diabetes, increased fracture risk, and disturbances in iron metabolism. This review explores the concept of ferroptosis, a non-apoptotic cell death process dependent on intracellular iron, focusing on its role in DOP. Iron-dependent lipid peroxidation, particularly impacting pancreatic β-cells, osteoblasts (OBs) and osteoclasts (OCs), contributes to DOP. The intricate interplay between iron dysregulation, which comprises deficiency and overload, and DOP has been discussed, emphasizing how excessive iron accumulation triggers ferroptosis in DOP. This concise overview highlights the need to understand the complex relationship between T2DM and OP, particularly ferroptosis. This review aimed to elucidate the pathogenesis of ferroptosis in DOP and provide a prospective for future research targeting interventions in the field of ferroptosis.

Citing Articles

Enhanced SIRT3 expression restores mitochondrial quality control mechanism to reverse osteogenic impairment in type 2 diabetes mellitus.

Xian Y, Liu B, Shen T, Yang L, Peng R, Shen H Bone Res. 2025; 13(1):30.

PMID: 40025004 PMC: 11873136. DOI: 10.1038/s41413-024-00399-5.

ZHX2 inhibits diabetes-induced liver injury and ferroptosis by epigenetic silence of YTHDF2.

Meng W, Li L Nutr Diabetes. 2025; 15(1):6.

PMID: 39987125 PMC: 11846978. DOI: 10.1038/s41387-025-00355-0.

Application of extracellular vesicles in diabetic osteoporosis.

Jia X, Zhang G, Yu D Front Endocrinol (Lausanne). 2024; 15:1466775.

PMID: 39720256 PMC: 11666354. DOI: 10.3389/fendo.2024.1466775.

Role of microRNA in Diabetic Osteoporosis.

Yuan Q, Wang Y, Hu S, Cai Z, Jiang L, Huang Y Mol Biotechnol. 2024; .

PMID: 39609335 DOI: 10.1007/s12033-024-01316-1.

Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects.

Ru Q, Li Y, Chen L, Wu Y, Min J, Wang F Signal Transduct Target Ther. 2024; 9(1):271.

PMID: 39396974 PMC: 11486532. DOI: 10.1038/s41392-024-01969-z.

References

Franke S, Ruster C, Pester J, Hofmann G, Oelzner P, Wolf G . Advanced glycation end products affect growth and function of osteoblasts. Clin Exp Rheumatol. 2011; 29(4):650-60. View

Uchizono Y, Takeya R, Iwase M, Sasaki N, Oku M, Imoto H . Expression of isoforms of NADPH oxidase components in rat pancreatic islets. Life Sci. 2006; 80(2):133-9. DOI: 10.1016/j.lfs.2006.08.031. View

Siddappa R, Mulder W, Steeghs I, van de Klundert C, Fernandes H, Liu J . cAMP/PKA signaling inhibits osteogenic differentiation and bone formation in rodent models. Tissue Eng Part A. 2009; 15(8):2135-43. DOI: 10.1089/ten.tea.2008.0512. View

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

Balogh E, Paragh G, Jeney V . Influence of Iron on Bone Homeostasis. Pharmaceuticals (Basel). 2018; 11(4). PMC: 6316285. DOI: 10.3390/ph11040107. View

An Y, Zhang H, Wang C, Jiao F, Xu H, Wang X . Activation of ROS/MAPKs/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated diabetic osteoporosis. FASEB J. 2019; 33(11):12515-12527. PMC: 6902677. DOI: 10.1096/fj.201802805RR. View

Jiao H, Xiao E, Graves D . Diabetes and Its Effect on Bone and Fracture Healing. Curr Osteoporos Rep. 2015; 13(5):327-35. PMC: 4692363. DOI: 10.1007/s11914-015-0286-8. View

Yuan H, Zhang X, Huang X, Lu Y, Tang W, Man Y . NADPH oxidase 2-derived reactive oxygen species mediate FFAs-induced dysfunction and apoptosis of β-cells via JNK, p38 MAPK and p53 pathways. PLoS One. 2011; 5(12):e15726. PMC: 3012098. DOI: 10.1371/journal.pone.0015726. View

Chu K, Leung P . Angiotensin II Type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young Type 2 diabetic mice. Antioxid Redox Signal. 2007; 9(7):869-78. DOI: 10.1089/ars.2007.1590. View

10.

Deng C, Cao J, Han J, Li J, Li Z, Shi N . Liraglutide Activates the Nrf2/HO-1 Antioxidant Pathway and Protects Brain Nerve Cells against Cerebral Ischemia in Diabetic Rats. Comput Intell Neurosci. 2018; 2018:3094504. PMC: 5829331. DOI: 10.1155/2018/3094504. View

11.

Pietrangelo A . Iron and the liver. Liver Int. 2016; 36 Suppl 1:116-23. DOI: 10.1111/liv.13020. View

12.

Zhao Y, Du Y, Gao Y, Xu Z, Zhao D, Yang M . ATF3 Regulates Osteogenic Function by Mediating Osteoblast Ferroptosis in Type 2 Diabetic Osteoporosis. Dis Markers. 2022; 2022:9872243. PMC: 9629949. DOI: 10.1155/2022/9872243. View

13.

Bellelli R, Federico G, Matte A, Colecchia D, Iolascon A, Chiariello M . NCOA4 Deficiency Impairs Systemic Iron Homeostasis. Cell Rep. 2016; 14(3):411-421. DOI: 10.1016/j.celrep.2015.12.065. View

14.

Ambachew S, Biadgo B . Hepcidin in Iron Homeostasis: Diagnostic and Therapeutic Implications in Type 2 Diabetes Mellitus Patients. Acta Haematol. 2017; 138(4):183-193. DOI: 10.1159/000481391. View

15.

Cuadrado A, Rojo A, Wells G, Hayes J, Cousin S, Rumsey W . Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019; 18(4):295-317. DOI: 10.1038/s41573-018-0008-x. View

16.

Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R . Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2015; 63(1):173-84. PMC: 4688087. DOI: 10.1002/hep.28251. View

17.

Liu Y, Tavana O, Gu W . p53 modifications: exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019; 11(7):564-577. PMC: 6736412. DOI: 10.1093/jmcb/mjz060. View

18.

Qu X, Sun Z, Wang Y, Ong H . Zoledronic acid promotes osteoclasts ferroptosis by inhibiting FBXO9-mediated p53 ubiquitination and degradation. PeerJ. 2022; 9:e12510. PMC: 8684721. DOI: 10.7717/peerj.12510. View

19.

Jiang Z, Wang H, Qi G, Jiang C, Chen K, Yan Z . Iron overload-induced ferroptosis of osteoblasts inhibits osteogenesis and promotes osteoporosis: An in vitro and in vivo study. IUBMB Life. 2022; 74(11):1052-1069. DOI: 10.1002/iub.2656. View

20.

Yan B, Ai Y, Sun Q, Ma Y, Cao Y, Wang J . Membrane Damage during Ferroptosis Is Caused by Oxidation of Phospholipids Catalyzed by the Oxidoreductases POR and CYB5R1. Mol Cell. 2020; 81(2):355-369.e10. DOI: 10.1016/j.molcel.2020.11.024. View